via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB:NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that CEO and Chief Medical Officer, Dr. Brian Murphy, will present at the upcoming NobleCon XV Annual Investor Conference and 8th Annual Glaucoma 360 New Horizons Forum.
<b>Biotech Showcase 2019</b>
Dr. Murphy will present a corporate overview at the NobleCon XV conference to be held on January 28-29, 2019 at the W Hotel in Fort Lauderdale, FL with follow-up investor meetings held throughout the conference.
Details of the presentation are as follows:
— <b>Date and Time:</b> Tuesday, January 29, 2019 at 11:30 AM EST
— <b>Location:</b> W Hotel, Fort Lauderdale, FL; Studio 2
To view the live webcast, please access the following link at the time of the presentation: http://noble.mediasite.com/mediasite/Play/ec2a154a20d948d0841a56e24dd602bd1d. An archived version of the webcast will be available for 90 days in the investor section of the Nemus Bioscience website.
<b>8th Annual Glaucoma 360 New Horizons Forum</b>
Dr. Brian Murphy, will present an overview of Nemus Bioscience’s cannabinoid pipeline for ocular diseases, including its lead candidate NB1111 for the management of glaucoma, at the 8 Annual Glaucoma 360 New Horizons Forum being held on Friday, February 1, 2019 at The Palace Hotel in San Francisco. This meeting, held by the Glaucoma Research Foundation, brings together key clinical and industry leaders in a unique exchange on research innovation and advances in glaucoma treatment.
Details of the presentation are as follows:
— <b>Session:</b> New Horizons in Drugs and Drops
— <b>Date and Time:</b> Friday, February 1, 2019 at 1:22-2:02 PM PST
— <b>Location:</b> The Palace Hotel, Grand Ballroom, San Francisco, CA
Thomas M. Brunner, President and CEO of Glaucoma Research Foundation, said, “This unique full-day meeting unites medicine, research, and industry, in order to advance new and promising developments in glaucoma.” He added, “We are honored to have Nemus Bioscience involved in this important endeavor.”
The 2019 meeting will feature more than 60 speakers from companies and institutions. Co-founded and co-chaired by Adrienne L. Graves, PhD and Andrew G. Iwach, MD<b>,</b> Glaucoma 360’s New Horizons Forum spotlights new and promising developments to diagnose and treat glaucoma, the leading cause of preventable blindness worldwide. Since its inception in 2012, this meeting has grown substantially, attracting attendees from across the United States and around the world.
<b>About Nemus Bioscience, Inc.</b>
The Company is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus’ strategy is to explore the use of proprietary biosynthetic compounds, alone or in combination with corporate partners. The Company is led by a highly qualified team of executives with decades of biopharmaceutical experience and a significant background in early-stage drug development.
For more information, visit www.nemusbioscience.com.
<b>FORWARD LOOKING STATEMENTS</b>
This press release contains forward-looking statements, including statements regarding our product development, business strategy, product milestones, EHS commitment to purchase shares in the open market, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “contemplates,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Nemus may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Nemus’ most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Nemus disclaims any intent or obligation to update these forward-looking statements.
This news release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any securities that may be offered in the United States will be offered only to accredited investors pursuant to Regulation D of the Securities Act.
CONTACT:Nemus Investor RelationsPCG Advisory GroupAdam HoldsworthEmail: email@example.comPhone: 646-862-4607Doug CesarioChief Financial OfficerEmail: firstname.lastname@example.orgPhone: 949-336-3437